Recruiting
Neoplasm
RecruitingStudy of ALE.
InvestigationalNo placebo
Study of ALE.
InvestigationalNo placebo
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ALE.P03
- Sponsor:Alentis Therapeutics AG
Back to ItalyClinical trials in Saronno – page 38
2 862 clinical trials in Saronno, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)Saronno at a glance
2 862
clinical trials
- Research sites1
Recruiting
Non-small cell lung cancer
RecruitingA Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
Registered drugNo placebo
A Study Comparing PF-08046054 to Docetaxel in Adults with Previously Treated PD-L1 Positive Non-Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:DocetaxelFetrastobart vedotin
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Pfizer Inc.
Recruiting
Breast cancer+3
RecruitingA Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment
Registered drugNo placebo
A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+2
- Substances:AbemaciclibGiredestrant+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
- Sponsor:Genentech Inc.
Recruiting
Cytomegalovirus infection+1
RecruitingA Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment
Registered drugNo placebo
A Study of Maribavir for Cytomegalovirus Infection in Stem Cell Transplant Patients Who Cannot Take or Did Not Tolerate Standard Treatment
Registered drugNo placebo
- Disease:Cytomegalovirus infectionAllogenic stem cell transplantation
- Substances:Maribavir
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Maribavir
- Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare
Recruiting
Investigational
A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments
Investigational
- Substances:RO7790121
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:RO7790121
- Sponsor:F. Hoffmann-La Roche AG
Recruiting
Hormone-refractory prostate cancer
RecruitingA Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment
Investigational
A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment
Investigational
- Disease:Hormone-refractory prostate cancer
- Substances:JNJ-78278343
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:JNJ-78278343
- Sponsor:Janssen Cilag International
Recruiting
Non-small cell lung cancer stage IV
RecruitingA Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
InvestigationalNo placebo
A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
InvestigationalNo placebo
- Disease:Non-small cell lung cancer stage IV
- Substances:AmivantamabLazertinib
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Amivantamab
- Sponsor:Janssen Cilag International
Recruiting
Cardiac failure
RecruitingA Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care
Registered drugNo placebo
A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care
Registered drugNo placebo
- Disease:Cardiac failure
- Substances:BisoprololCandesartan+23
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Bisoprolol
- Sponsor:Policlinico San Donato S.p.A.
Recruiting
Chronic obstructive pulmonary disease
RecruitingA Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
Registered drug
A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
Registered drug
- Disease:Chronic obstructive pulmonary disease
- Substances:DepemokimabSalbutamol Sulfate
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Depemokimab
- Sponsor:Glaxosmithkline Research & Development Limited
Recruiting
Diabetes mellitus
RecruitingA Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes
Investigational
A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes
Investigational
- Disease:Diabetes mellitus
- Substances:Teplizumab
Countries:Italy
Italy- Participants:0–17 years · 18–64 years
- Substances:Teplizumab
- Sponsor:Sanofi-Aventis Recherche & Developpement
Recruiting
Endometrial cancer metastatic
RecruitingA Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment
Registered drugNo placebo
- Disease:Endometrial cancer metastatic
- Substances:AZD8205Doxorubicin+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:AZD8205
- Sponsor:AstraZeneca AB
Recruiting
Hypertrophic cardiomyopathy+1
RecruitingA study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Investigational
- Disease:Hypertrophic cardiomyopathyCardiomyopathy
- Substances:Ninerafaxstat trihydrochloride monohydrate
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Ninerafaxstat trihydrochloride monohydrate
- Sponsor:Imbria Pharmaceuticals Inc.
Other cities in Italy
The busiest research cities in the country
Clinical research in Saronno
What the registry says about research in the country
01 Respiratory Oncology
Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, including studies evaluating novel therapeutic approaches for patients with specific genetic mutations.
- MET deregulation therapy assessment
- Second-line combination treatments
- EGFR mutation targeting
Research emphasizes personalized treatment strategies for advanced and metastatic disease states.
02 Women's Oncology
Comprehensive studies addressing breast cancer and gynecological malignancies, with focus on treatment timing and maintenance therapies.
- Endocrine-responsive breast cancer treatment
- Ovarian cancer maintenance therapy
- BRCA wild-type cancer management
Investigations aim to optimize treatment sequences and improve patient outcomes.
03 Specialized Oncology & Cardiology
Innovative research in renal cell carcinoma treatment and cardiac conditions, particularly focusing on novel therapeutic approaches.
- Metastatic renal cancer therapy
- Atrial fibrillation management
- Targeted combination therapies
Studies evaluate both oncological interventions and cardiovascular treatments for high-risk patients.